Merus N.V.
Merus N.V. is a Dutch public limited company (naamloze vennootschap) registered with the Netherlands Chamber of Commerce (KvK) under number 30189136. Incorporated on 16 June 2003, its registered office is at Uppsalalaan 17, 3584 CT Utrecht, Netherlands. Merus N.V. operated as a clinical-stage biotechnology company developing bispecific antibody therapeutics for cancer using its proprietary Biclonics platform, and its common shares traded on the Nasdaq Global Select Market under the ticker symbol MRUS until December 2025. The KvK register currently records Merus N.V.’s status as inactive, reflecting the corporate changes described below rather than a statement about its ongoing business, which continues under new ownership.
On 29 September 2025, Genmab A/S, a Danish biotechnology company, announced an agreement to acquire Merus N.V. in an all-cash transaction valuing the company at approximately USD 8.0 billion, offering USD 97.00 per common share. Genmab Holding II B.V., a wholly-owned Genmab A/S subsidiary, completed a tender offer for Merus N.V.’s shares on 12 December 2025 after receiving valid tenders for approximately 94.2% of outstanding shares, and completed a back-end merger cancelling the remaining shares on 29 December 2025, following a subsequent offering period that brought total tendered and cancelled shares to approximately 97.4%. Merus N.V.’s common shares ceased trading on Nasdaq before the opening of trading on 30 December 2025, and the company subsequently filed to deregister its shares and suspend its SEC reporting obligations. Merus N.V. is now a wholly-owned subsidiary of Genmab A/S. Its lead product candidate, petosemtamab, remained in Phase 3 clinical trials for head and neck cancer at the time of the acquisition, with Genmab anticipating a potential initial launch in 2027 subject to clinical and regulatory outcomes. For the year ended 31 December 2024, prior to the acquisition, Merus N.V. reported collaboration revenue of USD 36.1 million.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Shareholders of Merus N.V.
Prior to its acquisition, Merus N.V. was a Nasdaq-listed company with common shares held by institutional and public investors. Following completion of Genmab A/S’s acquisition, effective with the back-end merger and cancellation of remaining shares on 29 December 2025, all issued and outstanding common shares of Merus N.V. are held by Genmab Holding II B.V., a private limited liability company organized under the laws of the Netherlands and a wholly-owned subsidiary of Genmab A/S, a Danish public limited liability company. Genmab Holding II B.V. acquired the shares via a tender offer completed 12 December 2025, in which approximately 94.2% of outstanding shares were validly tendered, followed by a subsequent offering period through 29 December 2025 that brought tendered shares to approximately 97.4%, with the remaining shares cancelled in the back-end merger for the same USD 97.00-per-share cash consideration. Institutional shareholders previously reported in connection with Merus N.V.’s Nasdaq listing no longer hold shares in the company following this transaction.
Data availability
Classification: Full. Merus N.V.’s current sole-shareholder position is confirmed through Genmab A/S’s and Merus N.V.’s SEC filings and joint press releases describing the completed tender offer and back-end merger; historical Nasdaq-era institutional shareholder records are superseded by this transaction.
Sources
- Merus N.V. / Genmab A/S – “Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period,” ir.merus.nl, 12 December 2025
- U.S. Securities and Exchange Commission – Merus N.V. Schedule TO-T / Schedule 14D-9 filings, CIK 0001651311, 2025
- Investing.com – “Genmab completes acquisition of Merus and delists shares from Nasdaq,” December 2025
Registry feed — rows exactly as filed with Netherlands Chamber of Commerce (KvK), including entries the profile above does not cover.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Columbia Funds Series Trust I-Columbia Cornerstone Growth Fund | 1.6% | Netherlands Chamber of Commerce (KvK) | |
| iShares Trust-iShares Biotechnology ETF | 1.3% | Netherlands Chamber of Commerce (KvK) | |
| T. Rowe Price Health Sciences Fund, Inc. | 1.2% | Netherlands Chamber of Commerce (KvK) | |
| Fidelity Hastings Street Trust-Fidelity Series Large Cap Stock Fund | 0.9% | Netherlands Chamber of Commerce (KvK) | |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 0.9% | Netherlands Chamber of Commerce (KvK) |
Officers
18
Directors and officers of Merus N.V.
Upon the closing of Genmab A/S’s acquisition of Merus N.V. on 12 December 2025, Merus N.V.’s board of directors was substantially reconstituted. Directors Sven (Bill) Ante Lundberg, M.D., Mark Iwicki, Len Kanavy, Paolo Pucci, Victor Sandor, M.D.C.M., and Jason Haddock ceased to serve as directors, while Maxine Gowen, Ph.D. and Anand Mehra, M.D. continued as directors. Jan van de Winkel, Ph.D., Greg Mueller, Anthony Pagano and Martine van Vugt, Ph.D. were appointed as directors effective the same date, with Dr. van de Winkel serving as executive director and Chief Executive Officer and the other three as non-executive directors. Sven (Bill) Ante Lundberg, M.D. and Peter Silverman also ceased to serve as executive officers of the company at closing. This overview reflects Merus N.V.’s SEC Form 8-K filing dated 12 December 2025; nationality and country-of-residence information for the current directors was not disclosed in that filing.
Recent officer changes
- Jan van de Winkel, Ph.D. appointed Director and Chief Executive Officer, 12 December 2025 (source: SEC Form 8-K).
- Greg Mueller, Anthony Pagano and Martine van Vugt, Ph.D. appointed non-executive Directors, 12 December 2025 (source: SEC Form 8-K).
- Six legacy directors – Sven (Bill) Ante Lundberg, Mark Iwicki, Len Kanavy, Paolo Pucci, Victor Sandor and Jason Haddock – ceased to serve as directors upon closing of the Genmab acquisition, 12 December 2025 (source: SEC Form 8-K).
Data availability
Classification: Partial. The 12 December 2025 board reconstitution is confirmed by Merus N.V.’s own SEC filing; that filing does not report nationality, country of residence or appointment dates for the newly appointed directors, and the Netherlands Chamber of Commerce register consulted for this profile had not yet reflected the post-acquisition board at the time of review.
Sources
- Merus N.V. – Form 8-K, U.S. Securities and Exchange Commission, filed 12 December 2025 (CIK 0001651311)
- Investing.com – “Genmab completes $6.9 billion acquisition of Merus N.V., triggers leadership changes,” December 2025
Registry feed — rows exactly as filed with Netherlands Chamber of Commerce (KvK), including entries the profile above does not cover.
Group Structure
Group structure of Merus N.V.
Merus N.V. is not an independent company. Following completion of Genmab A/S’s acquisition, effective 29 December 2025, Merus N.V.’s immediate parent is Genmab Holding II B.V., a private limited liability company organized under the laws of the Netherlands and a wholly-owned subsidiary of Genmab A/S. Genmab A/S, a public limited liability company organized under the laws of Denmark and listed on Nasdaq Copenhagen and the Nasdaq Global Select Market (ticker GMAB), is Merus N.V.’s ultimate parent. No subsidiaries of Merus N.V. were identified during this research. Group information reflects Genmab A/S’s and Merus N.V.’s SEC filings and press releases relating to the acquisition, dated December 2025.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Genmab Holding II B.V. | NL | Not disclosed in reviewed sources | Immediate parent | 100% of issued shares | Active | 29 Dec 2025 |
| Genmab A/S | DK | DK 21023884 | Ultimate parent | Wholly owns Genmab Holding II B.V. | Active | 29 Dec 2025 |
Recent structural changes
- Genmab A/S completed its acquisition of Merus N.V. via tender offer and back-end merger, effective 12–29 December 2025, making Merus N.V. a wholly-owned subsidiary of Genmab A/S (source: SEC filings; Genmab A/S and Merus N.V. press releases).
Data availability
Classification: Full for the immediate and ultimate parent relationship, confirmed through SEC filings and joint press releases; Not found for any subsidiaries of Merus N.V., which were not identified during this research.
Sources
- Genmab A/S – “Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period,” ir.genmab.com, 12 December 2025
- U.S. Securities and Exchange Commission – Merus N.V. and Genmab A/S filings, CIK 0001651311, December 2025
GENMAB A/S
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does Merus N.V. do?
Merus N.V. (KvK 30189136) is a Dutch clinical-stage biotechnology company, incorporated 16 June 2003 and registered in Utrecht, Netherlands, that developed bispecific antibody therapeutics for cancer using its Biclonics platform, including lead candidate petosemtamab, before becoming a wholly-owned subsidiary of Genmab A/S in December 2025.
Who owns Merus N.V.?
As of 29 December 2025, all outstanding common shares of Merus N.V. are held by Genmab Holding II B.V., a wholly-owned subsidiary of Genmab A/S, following a completed tender offer and back-end merger; no other shareholders remain.
Who is Merus N.V.'s UBO (Ultimate Beneficial Owner)?
No natural-person ultimate beneficial owner has been identified for Merus N.V.; its ultimate parent, Genmab A/S, is a publicly traded Danish company.
What is Merus N.V.'s company registration number?
Merus N.V.'s registration number is 30189136, filed with Netherlands Chamber of Commerce (KvK) in Netherlands. Its current status on the register is inactive.
Is Merus N.V. still an active company?
Merus N.V.'s status on Netherlands Chamber of Commerce (KvK) is listed as inactive, not currently active.
When was Merus N.V. incorporated?
Merus N.V. was incorporated on 16 June 2003, according to Netherlands Chamber of Commerce (KvK).
What is Merus N.V.'s registered address?
The registered address on file for Merus N.V. is Utrecht, Netherlands.
What is Merus N.V.'s revenue?
Merus N.V. reported collaboration revenue of USD 36.1 million for the year ended 31 December 2024, according to its SEC filings, prior to its acquisition by Genmab A/S.
Is Merus N.V. listed on a stock exchange?
Merus N.V.'s common shares traded on the Nasdaq Global Select Market under the ticker MRUS until they were delisted on 30 December 2025 following completion of Genmab A/S's acquisition.
Who are the officers/directors of Merus N.V.?
Merus N.V.'s board was reconstituted on 12 December 2025, with Jan van de Winkel, Ph.D. appointed Director and CEO alongside three new non-executive directors, while six legacy directors ceased to serve, per the company's SEC Form 8-K filing.
Does Merus N.V. have a parent company or subsidiaries?
Merus N.V.'s immediate parent is Genmab Holding II B.V. (Netherlands), and its ultimate parent is Genmab A/S (Denmark, Nasdaq: GMAB), following completion of Genmab's acquisition of Merus N.V. in December 2025.
Can Zavia monitor changes to Merus N.V.'s ownership over time?
This profile reflects a point-in-time snapshot from Netherlands Chamber of Commerce (KvK). Zavia's monitoring API can track changes to Merus N.V.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access Merus N.V.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Netherlands, so records like Merus N.V.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Netherlands Chamber of Commerce (KvK) and was last synced on 18 September 2026.